- My earlier article on the iShares Biotechnology ETF (IBB) analyzed its exposure to the leading biotech and pharmaceutical companies, its diversification, and its innovation.
- Thanks to these factors, IBB has delivered excellent returns in the past. But the current market valuation is at a historical high and the fund has suffered large volatility risks.
- The combination of high volatility and high valuation calls for hedging ideas, and this article describes such an idea after analyzing the fund’s fundamentals.
For further details see:
IBB: Risks And Hedging